Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin.

A Bera, X-M Leighton, H Pollard, M Srivastava

Open access · greenAbstract read

In one paragraph

Article in Trends in cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it

0cells of the map it votes in

5citing papers in PubMed

0.5field-weighted citation impact, top 35% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

Exploring the Structural and Functional Diversity among FGF Signals: A Comparative Study of Human, Mouse, and Xenopus FGF Ligands in Embryonic Development and Cancer Pathogenesis.International journal of molecular sciences · 2023
Review
AnnexinA7 promotes epithelial-mesenchymal transition by interacting with Sorcin and contributes to aggressiveness in hepatocellular carcinoma.Cell death & disease · 2021
Article
FGF/FGFR signaling in health and disease.Signal transduction and targeted therapy · 2020
Review
Prognostic roles of miR-124-3p and its target ANXA7 and their effects on cell migration and invasion in hepatocellular carcinoma.International journal of clinical and experimental pathology · 2020
Article
Downregulation of annexin A7 decreases proliferation, migration, and invasion of gastric cancer cells by reducing matrix metalloproteinase 1 and 9 expression.American journal of translational research · 2019
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

A BeraDepartment of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University of Health Sciences (USUHS) School of Medicine, Bethesda, MD 20814, USA.

X-M LeightonDepartment of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University of Health Sciences (USUHS) School of Medicine, Bethesda, MD 20814, USA.

H PollardDepartment of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University of Health Sciences (USUHS) School of Medicine, Bethesda, MD 20814, USA.

M SrivastavaDepartment of Anatomy, Physiology and Genetics, and Institute for Molecular Medicine, Uniformed Services University of Health Sciences (USUHS) School of Medicine, Bethesda, MD 20814, USA.

Uniformed Services University of the Health Sciences · US

Funding

Intramural NIH HHS Z99 LM999999

6 · The paper itself

Abstract

Tumor suppressor function of Annexin-A7 (ANXA7) was demonstrated by cancer-prone phenotype in

Indexed as

annexin A7cyclin Efibroblast growth factor 8 (FGF8)prostate and breast cancertumor suppression

Identifiers

PMID30369774

PMCPMC6200414

OpenAlexW3025239472

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.